Antidepressant treatment patterns and costs among US employees

Journal of Medical Economics

Volumn 12, Issue 1, 2009, Pages 36-45

  Birnbaum, Howard ^a   Greenberg, Paul E ^a   Tang, Jackson ^a   Hsieh, Matthew ^a   Wu, Eric Q ^a   Amand, Caroline ^b   Ben Hamadi, Rym ^a  

^a ANALYSIS GROUP   (United States)

^b SANOFI   (France)

Author keywords

Antidepressants; Cost; Depression; Treatment patterns

Indexed keywords

AMFEBUTAMONE; NORADRENALIN UPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR;

ADULT; ARTICLE; COMPARATIVE STUDY; CONTROL GROUP; CONTROLLED STUDY; COST CONTROL; DEPRESSION; DRUG COST; EMPLOYEE; FEMALE; HEALTH CARE COST; HEALTH INSURANCE; HUMAN; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MULTIVARIATE ANALYSIS; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; PRESCRIPTION; UNITED STATES;

ADULT; ANALYSIS OF VARIANCE; ANTIDEPRESSIVE AGENTS; COST-BENEFIT ANALYSIS; DEPRESSIVE DISORDER, MAJOR; FEMALE; HEALTH BENEFIT PLANS, EMPLOYEE; HUMANS; INSURANCE CLAIM REVIEW; MALE; UNITED STATES;

EID: 67649625198     PISSN: 13696998     EISSN: None     Source Type: Journal    
DOI: 10.3111/13696990902757389     Document Type: Article

References (25)

1. Greenberg PE, Kessler RC, Birnbaum HG, et al. The economic burden of depression in the United States: how did it change between 1990 and 2000? J Clin Psychiatry 2003;64(12):1465-1475.
2. Kessler RC, Berglund P, Demler O, et al. National Comorbidity Survey Replication. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA 2003;289(23):3095-3105.
3. Bloom BS. Prevalence and economic effects of depression. Manag Care 2004;13(6 Suppl):9-16.
4. Greenberg PE, Stiglin LE, Finkelstein SN, Berndt ER. The economic burden of depression in 1990. J Clin Psychiatry 1993;54(11):405-418.
5. Murray CJ, Lopez AD. Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study. Lancet 1997;349(9064):1498- 1504.
6. Kessler RC, Akiskal HS, Ames M, et al. Prevalence and effects of mood disorders on work performance in a nationally representative sample of U.S. workers. Am J Psychiatry 2006;163(9):1561-1568.
7. Crown WH, Finkelstein S, Berndt ER, et al. The impact of treatment-resistant depression on health care utilization and costs. J Clin Psychiatry 2002;63:963-971.
8. Corey-Lisle PK, Birnbaum H, Greenberg PEP, et al. Identification of a claims data "signature" and economic consequences for treatment-resistant depression. J Clin Psychiatry 2002;63(8):717-726.
9. Russell JM, Hawkins K, Ozminkowski RJ, et al. The cost consequences of treatment-resistant depression. J Clin Psychiatry 2004;65(3):341-347.
10. Greenberg PE, Corey-Lisle PK, Birnbaum H, et al. Economic implications of treatment-resistant depression among employees. Pharmacoeconomics 2004;22(6):363-373.
11. Thompson D, Buesching D, Gregor KJ, Oster G. Patterns of antidepressant use and their relation to costs of care. Am J Manage Care 1996;2:1239-1246.
12. Simon GE. Evidence review: efficacy and effectiveness of antidepressant treatment in primary care. Gen Hosp Psychiatry 2002;24(4):213-224.
13. Melfi CA, Chawla AJ, Croghan TW, et al. The effects of adherence to antidepressant treatment guidelines on relapse and recurrence of depression. Arch Gen Psychiatry 1998;55(12):1128-1132.
14. Melartin TK, Rytsala HJ, Leskela US, et al. Continuity is the main challenge in treating major depressive disorder in psychiatric care. J Clin Psychiatry 2005;66(2):220-227.
15. Antidepressant Medication Management. The state of health care quality, National Committee for quality assurance. Washington, DC: 2006;1.
16. Akincigil A, Bowblis JR, Levin C, et al. Adherence to antidepressant treatment among privately insured patients diagnosed with depression. Med Care 2007;45(4):363-369.
17. Burton WN, Chen CY, Conti DJ, et al. The association of antidepressant medication adherence with employee disability absences. Am J Manag Care 2007;13(2):105-112.
18. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 1992;45:613-619.
19. Duan N, Manning WG, Morris CN, Newhouse JP. A comparison of alternative models for the demand for medical care. J Bus Econ Stat 1983;1(2):115-126.
20. Wedderburn RWM. Quasi-likelihood functions, generalized linear models, and the Gauss-Newton method. Biometrika 1974;61:439-447.
21. Manning WG, Mullahy J. Estimating log models: to transform or not to transform? J Health Econ 2001;20:461-494.
22. Manning WG. The logged dependent variable, heteroscedasticity, and the retransformation problem. J Health Econ 1998; 17:283-295.
23. Trivedi MH, Rush AJ, Wisniewski SR, et al. and STAR*D Study Team. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry 2006;163:28-40.
24. Rush AJ, Trivedi MH, Wisniewski SR, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: A STAR*D Report. Am J Psychiatry 2006;163(11):1905-17.
25. Birnbaum H, Ben-Hamadi R, Greenberg P, et al. Determinants of direct cost differences among U.S employees with major depressive disorders using antidepressants. Pharmacoeconomics, forthcoming.